ProQR Therapeutics has successfully demonstrated human pharmacological activity using its RNA editing platform, particularly with AX-0810 in Phase 1 trials. The company focuses on treating rare pediatric liver disease, biliary atresia, aiming for a faster and cleaner clinical validation than competitors. Recent funding rounds, including a $50 million direct offering and a $9.2 million investment from Eli Lilly, extend its cash runway to mid-2027, supporting multiple clinical programs. Upcoming catalysts include further data from AX-0810/AX-0811 and the start of a pediatric biliary atresia trial, with valuation now dependent on clinical execution, safety, and durability.
Chery Auto officially opened its Rosslyn Plant in South Africa, transforming from an importer to a local manufacturer and retaining all 692 employees. The plant, originally built in 1963, will be upgraded to produce 50,000 vehicles annually by mid-20...
Aave's new lending market on the Monad blockchain surpassed $100 million in deposits within 48 hours of launching on July 2, 2026. Monad is a high-speed, EVM-compatible Layer 1 chain known for its fast transaction speeds, making it attractive for DeF...
The MARS2 Multimodal Reasoning Competition, sponsored by Tec-Do and MiniMax, has been officially launched to coincide with the ECCV 2026 conference. With a $100,000 prize pool, the competition challenges AI models to perform complex, open-world reaso...
Zcash is preparing for the Ironwood network upgrade set to launch on July 21, 2026, which will allow node operators to verify the coin's circulating supply directly. This upgrade addresses a critical privacy flaw discovered in the Orchard shielded po...
Open USD introduces a new stablecoin model that shares reserve yield with distribution partners instead of the issuer, aiming to realign incentives for wallets, payment processors, and fintechs. This approach could disrupt USDC's long-standing domina...
